4Feldman SR,Evans C,Russell MW.Systemic treatment for moderate to severe psoriasis:estimates of failure rates and direct medical costs in a north-eastern US managed care plan[J].J Dermatolog Treat,2005,16(1):37-42.
5Brunasso AM,Puntoni M,Salvini C,et al.Tolerability and safety of biological therapies for psoriasis in daily clinical practice:a study of 103 Italian patients[J].Acta Derm Venereol,2011,91 (1):44-49.
6Gniadecki R,Kragballe K,Dam TN,et al.Comparison of drug survival rates for adalimumab,etanercept and infliximab in patients with psoriasis vulgaris[J].Br J Dermatol,2011,164(5):1091-1096.
7Mrowietz U,Kragballe K,Reich K,et al.Definition of treatment goals for moderate to severe psoriasis:a European consensus[J].Arch Dermatol Res,2011,303(1):1-10.
8Johnson-Huang LM,Pensabene CA,Shah KR,et al.Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs[J/OL].PLoS One,2012,7 (2):e30308[2013-08-01].http://www.plosone.org/article/info% 3 Adoi %2F 10.1371%2Fjournal.pone.0030308.
9Suárez-Fari(n)as M,Fuentes-Duculan J,Lowes MA,et al.Resolved psoriasis lesions retain expression of a subset of disease-related genes[J].J Invest Dermatol,2011,131 (2):391-400.
10van de Kerkhof PC,Mali JW.Methotrexate maintenance following Ingram therapy in 'difficult' psoriasis[J].Br J Dermatol,1982,106(6):623-627.
